Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio, Inc. (KRRO) reported that Senior Vice President, Finance Oliver Dolan sold a total of 7,353 shares of Common Stock on September 8–9, 2026 in open-market or private transactions made pursuant to a Rule 10b5-1 trading plan adopted on June 8, 2026.
The September 8 sale covered 7,347 shares at a weighted-average price of $13.5138 per share, with prices ranging from $13.50 to $13.595. The September 9 sale covered 6 shares at a weighted-average price of $13.6033, with prices ranging from $13.52 to $13.76. Following these transactions, Dolan’s holdings include 16,241 shares issuable upon settlement of unvested RSUs, consisting of 10,741 shares scheduled to vest on December 15, 2026, 2,750 on July 15, 2027, and 2,750 on July 15, 2028, each subject to maintaining a continuous Service Relationship.
Korro Bio, Inc. (KRRO) is the issuer for a planned sale of common stock reported under Rule 144 by James (Oliver) O. Dolan. The notice lists a small number of common shares to be sold following restricted stock vesting on June 15, 2026, with prior sales of vested shares already made in June and September 2026.
Korro Bio, Inc. (KRRO) received a Rule 144 notice that officer James O. (Oliver) Dolan intends to sell 7,347 shares of common stock, held at Fidelity Brokerage Services LLC. The shares relate to restricted stock vesting on June 15, 2026. Over the prior three months, Dolan sold 3,383 common shares for $36,638.23.
Korro Bio, Inc. (KRRO) director Jean Francois Formela, through investment funds associated with Atlas Venture, reported indirect sales of a total of 300 shares of common stock on August 26, 2026. The shares were sold pursuant to a Rule 10b5-1 trading plan at a weighted average price of about $13.96 per share, in multiple trades between $13.955 and $13.98. The shares are held by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., and Formela disclaims Section 16 beneficial ownership except to the extent of his pecuniary interest.
Korro Bio, Inc. (KRRO) is the issuer in a notice that Atlas Venture Fund XI, L.P. intends to sell 249 shares of common stock under Rule 144 through Merrill Lynch. The planned sale has an aggregate market value of $3,418.77, with 14,725,646 shares of common stock stated as outstanding as of the notice. The shares were originally acquired from Korro Bio in a private placement on March 23, 2023 for cash. The filing also lists multiple prior Rule 144 sales over the past three months by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P.
Korro Bio, Inc. (KRRO) is the issuer for a notice by Atlas Venture Opportunity Fund II, L.P. to sell common stock under Rule 144. The filing indicates a proposed sale of 51 shares of Korro Bio common stock through Merrill Lynch with an aggregate market value of $700.23, at a time when 14,725,646 shares of common stock were outstanding. The filing also lists multiple recent secondary-market sales of Korro Bio common stock by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., including a block of 101,579 shares sold on June 23, 2026 for $1,447,785.17.
Korro Bio, Inc. (KRRO) director Jean Francois Formela reported indirect open-market sales of Korro Bio common stock by venture funds with which he is associated. On August 19, 2026, Atlas Venture Fund XI, L.P. sold 23,584 shares and Atlas Venture Opportunity Fund II, L.P. sold 4,884 shares, totaling 28,468 shares at a weighted average price of $14.00 per share, under a Rule 10b5-1 trading plan. The shares are held by the Atlas funds; Formela disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest.
Korro Bio, Inc. (KRRO) has a notice of proposed resale of restricted common stock under Rule 144 by Atlas-affiliated funds. Atlas Venture Fund XI, L.P. plans to sell 23,584 shares, while disclosures list prior open-market sales by Atlas Venture Fund XI and Atlas Venture Opportunity Fund II over the past three months.
Korro Bio, Inc. (KRRO) is the issuer of common stock for which Atlas Venture Opportunity Fund II, L.P. has filed a notice of proposed resale under Rule 144. The fund indicates an intention to sell 4,884 shares of Korro Bio common stock through Merrill Lynch on Nasdaq.
The shares to be sold were originally acquired on April 22, 2024 in a private placement for cash. The notice also lists multiple Korro Bio share sales during the past three months by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., with individual transactions ranging from hundreds to over one hundred thousand shares.
Korro Bio, Inc. (KRRO) reports that on August 19, 2026 it submitted materials to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121. KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide being developed for the potential treatment of hyperammonemia in patients with Urea Cycle Disorders.
The planned Phase 1/2 study is designed to evaluate safety and tolerability of escalating doses, characterize pharmacokinetics, and assess effects in both healthy volunteers and participants with Urea Cycle Disorders. Additional trial details are available at ClinicalTrials.gov under identifier NCT 07773246.